Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan. Usuki K, Ikezoe T, Ishiyama K, Kanda Y, et al. Int J Hematol 2023;118:311-322.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Usuki K, Ikezoe T, Ishiyama K, Kanda Y, et al. Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol 2023;118:311-322.
PMID: 37477863